Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

NCT05218629 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Overall Survival

Interventions

DRUG: Anlotinib, PD-1 inhibitor

Sponsor

Qingdao Central Hospital